Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07093073RecruitingPhase 1
CAR-T therapy for B-cell lymphoma
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
ShanghaiAges 2–75 - NCT07087158RecruitingPhase 2
IBR854 plus pazopanib vs pazopanib for advanced kidney cancer
This trial tests a new combination therapy (IBR854 plus pazopanib) against pazopanib alone for people with advanced clear cell kidney cancer who haven't had prior treatment. It aims to see if the combination works better.
ShanghaiAges 18 years+ - NCT07095608Recruiting
Study on nerve cells and oral cancer pain
This study looks at how certain nerve cells might be involved in oral cancer pain. It aims to find new ways to treat pain by testing tissue samples from people with oral cancer and healthy volunteers.
New York, New YorkAges 18 years+ - NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT07086469RecruitingPhase 2
Surufatinib plus chemo-immunotherapy before chemoradiation for advanced esophageal cancer
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Guangzhou, GuangdongAges 18–80 - NCT07088354Recruiting
AI model predicts treatment response in esophageal cancer
This trial tests whether an artificial intelligence (AI) model can accurately predict if esophageal cancer will completely disappear after chemotherapy combined with immunotherapy before surgery. If successful, it could help doctors decide the best treatment plan for patients.
Wuhan, HubeiAges 18 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07093710RecruitingPhase 1/Phase 2
Golidocitinib combo for relapsed peripheral T-cell lymphoma
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
Guangzhou, GuangdongAges 18 years+ - NCT07090668Recruiting
Ear stimulation for pain in sickle cell disease
This trial tests a safe, non-drug device that gently stimulates the ear to help reduce pain in children with sickle cell disease who are in the hospital for a pain crisis. It may offer a new way to manage pain without extra medication.
Atlanta, GeorgiaAges 7–18 - NCT06092047RecruitingEarly Phase 1
UTAA09 injection for relapsed or refractory blood cancers
This trial tests an investigational cell therapy called UTAA09 for people with CD19-positive B-cell blood cancers that have come back or not responded to treatment. It aims to see if this treatment is safe and effective.
Hefei, AnhuiAges 3–70 - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT07082686RecruitingPhase 2
A study of ICP-248 for mantle cell lymphoma that has come back or not responded
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
Hefei, AnhuiAges 18 years+ - NCT07080437Recruiting
Immunotherapy and chemoradiation for elderly esophageal cancer patients
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT07078500RecruitingPhase 2
Orelabrutinib plus Pola-R-CHP for untreated non-GCB DLBCL
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hangzhou, ZhejiangAges 18–80 - NCT07084610RecruitingPhase 2
Metabolic markers predict response to immunotherapy before lung cancer surgery
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
Ribeirão Preto, São PauloAges 18 years+ - NCT07084480Recruiting
A study on giant cell arteritis for precision medicine
This trial looks at giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) to find more personalized treatments. If you have been diagnosed with either condition, you may be able to help researchers understand these diseases better.
WürzburgAges 18 years+ - NCT07084155Recruiting
Cell phone support for teens with chronic conditions
This trial tests a cell phone program to help teens manage their daily medications. It aims to make sticking to a medication routine easier for young people with long-term health conditions.
Los Angeles, CaliforniaAges 15–20 - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT06358222Recruiting
Lung cancer trial testing blood test and PET scan for spread
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
ShanghaiAges 18–75 - NCT06659042RecruitingPhase 2
Tislelizumab before and after surgery for KRAS-mutated lung cancer
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06744296Recruiting
ctDNA surveillance for HPV-negative head and neck cancer
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
Boston, MassachusettsAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.